

Cover Story
COVID-19 & CancerGuest Editorial
By Jeremy L. Warner and Sanjay Mishra
As we head into the third year of the global COVID-19 pandemic, everyone would just like it to be over.
COVID-19 & Cancer
By Matthew Bin Han Ong, Alexandria Carolan and Alice Tracey
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - In The Headlines: Private funding can’t replace federal funding—but it can help
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”